R., Sapieha, P., Dutta, S., Sun, J
PMID 3300262
Nov 02, 2023, 13:30 ET Mounjaro delivered superior HbA1c reductions versus Ozempic (semaglutide) 1 mg in the phase 3 SURPASS-2 clinical trial While not indicated for weight management, Mounjaro led to significantly greater weight reductions versus the comparator, Ozempic 1 mg, as a key secondary endpoint Mounjaro represents the first new class of diabetes medicines introduced in nearly a decade and is now available for Canadian patients TORONTO, Nov
The thickness and length allow precise delivery into deeper muscle layers
I switched to Fast n Up as it doesnt contain any artificial colouring
Its essential to note that tirzepatide reduced body weight more than semaglutide (1.0 mg weekly), with a 15 mg dose resulting in a body weight loss of over 20% as opposed to the usual 15-20% with Ozempic